title: Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.
abstract: OBJECTIVE
  Cyclooxygenase-2 (COX-2) has been claimed to play role in carcinogenesis and be related to a bad prognosis in tumours. The aim of this study was to investigate the relationship between COX-2 expression and clinical and pathological parameters in early and advanced stage lung cancer patients.
  
  
  METHODS
  A total of 73 patients with lung cancer (27 adenocarcinomas, 33 squamous cell carcinomas, 4 large cell carcinomas and 9 small cell cancer) were analysed retrospectively. COX-2 expression was evaluated by immunohistochemistry in resection materials or lung biopsies. Tumor cells demonstrating more intense staining than smooth muscle and endothelial cells were recorded as COX-2 positive. We investigated the correlation between increased COX-2 expression and histological type of the tumor, the stage of the disease and survival.
  
  
  RESULTS
  COX-2 expression was observed in 55% of the adenocarcinomas, 45% of the squamous cell carcinomas and 22% of the small cell carcinomas. No correlation was apparent between COX-2 expression and disease stage, histological type and the survival.
  
  
  CONCLUSIONS
  The results of this study do not support COX-2 expression as an independent prognostic factor in lung cancer. However, since results of the literature are different, further studies made in larger series are needed.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. hmehmetturk@gmail.com
authors.forename: H Mehmet
authors.initials: HM
authors.lastname: Turk
authors.forename: Celalettin
authors.initials: C
authors.lastname: Camci
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Suleyman
authors.initials: S
authors.lastname: Bukyukberber
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Sari
authors.forename: Mustafa
authors.initials: M
authors.lastname: Adli
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018287:Carcinoma, Large Cell / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D059186:Chemoradiotherapy, Adjuvant; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human